PTAB Finds Good Cause for Staying Ex Parte Reexamination in Light of Parallel IPR

Jul 12, 2019

Reading Time : 2 min

On September 11 2018, Petitioner filed a petition for IPR of U.S. Patent No. 6,651,864, which is directed to devices and methods for bonding electrical connections. Independent claim 28 was the only claim challenged in the petition. The Board instituted the IPR on March 14, 2019. Approximately one month later, on April 16 2019, a third party requested ex parte reexamination of claims 1, 2, 4, 7 and 28 of the ’864 Patent. After the Board granted the reexamination request, Patent Owner filed a motion to stay the reexamination proceeding pending resolution of the IPR.

In addressing the motion, the Board explained that a party seeking a stay of a reexamination must show there is “good cause” to warrant the stay. In deciding whether “good cause” exists, the Patent Office has recently identified several factors that the Board may consider, including:

  1. whether the claims challenged in the IPR are the same as or depend directly or indirectly from claims at issue in the reexamination;
  2. whether the same grounds of unpatentability or the same prior art are at issue in both the IPR and the reexamination;
  3. whether simultaneous conduct of the reexamination and IPR will duplicate efforts within the Office;
  4. whether the reexamination could result in inconsistent results with the IPR;
  5. whether amending the claim scope in one proceeding would affect claim scope in the other;
  6. the respective timelines and stages of each proceeding;
  7. the statutory deadlines of the reexamination and IPR; and
  8. whether a decision in the IPR would likely simplify issues presented in the reexamination or render it moot.

See Notice, 84 Fed. Reg. at 16,657 (April 22, 2019).

The Board weighed these factors and granted the motion to stay the reexamination despite there being only one claim (claim 28) in common between the IPR and reexamination proceedings. The Board found that substantial overlap in prior art between the two proceedings favored the stay and expressed concern that moving forward with both proceedings could lead to “wasteful duplication of effort” by the Office, with potentially “inconsistent factual determinations and legal conclusions.” Finally, the Board noted that the reexamination was still at an early stage, and the Patent Office had not issued a first Office Action, whereas the Patent Owner had already submitted its Preliminary Response in the IPR proceeding. Considering the factors in total, the Board concluded there was “good cause” to stay the reexamination until completion of the IPR.

Practice Tip: A party seeking the stay of an ex parte reexamination, where the same patent is being challenged in an IPR, should be prepared to show good cause by addressing the factors enunciated by the Office as meriting consideration in determining such a request.

Toshiba Memory Corp. v. Anza Tech., Inc., IPR2018-01598, Paper 35 (PTAB July 10, 2019)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.